{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:25:03Z","timestamp":1791318303454,"version":"4.3.1"},"reference-count":130,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2022,8,20]],"date-time":"2022-08-20T00:00:00Z","timestamp":1660953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Canadian Institutes of Health Research (CIHR)","award":["# CC1-177334"],"award-info":[{"award-number":["# CC1-177334"]}]},{"name":"Canadian Institutes of Health Research (CIHR)","award":["#296306"],"award-info":[{"award-number":["#296306"]}]},{"name":"CIHR Canadian HIV Trials Network","award":["# CC1-177334"],"award-info":[{"award-number":["# CC1-177334"]}]},{"name":"CIHR Canadian HIV Trials Network","award":["#296306"],"award-info":[{"award-number":["#296306"]}]},{"name":"CIHR postdoctoral fellowship","award":["# CC1-177334"],"award-info":[{"award-number":["# CC1-177334"]}]},{"name":"CIHR postdoctoral fellowship","award":["#296306"],"award-info":[{"award-number":["#296306"]}]},{"name":"FRSQ-S Chercheur Boursier Clinicien Senior","award":["# CC1-177334"],"award-info":[{"award-number":["# CC1-177334"]}]},{"name":"FRSQ-S Chercheur Boursier Clinicien Senior","award":["#296306"],"award-info":[{"award-number":["#296306"]}]},{"name":"recipient of an FRQ-S Junior 2 Chercheur Boursier Clinicien career award","award":["# CC1-177334"],"award-info":[{"award-number":["# CC1-177334"]}]},{"name":"recipient of an FRQ-S Junior 2 Chercheur Boursier Clinicien career award","award":["#296306"],"award-info":[{"award-number":["#296306"]}]},{"name":"Canadian Federal Tri-Agency","award":["# CC1-177334"],"award-info":[{"award-number":["# CC1-177334"]}]},{"name":"Canadian Federal Tri-Agency","award":["#296306"],"award-info":[{"award-number":["#296306"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Nonalcoholic fatty liver disease (NAFLD), alcohol-induced liver disease (ALD), and viral hepatitis are the main causes of morbidity and mortality related to chronic liver diseases (CLDs) worldwide. New therapeutic approaches to prevent or reverse these liver disorders are thus emerging. Although their etiologies differ, these CLDs all have in common a significant dysregulation of liver metabolism that is closely linked to the perturbation of the hepatic endocannabinoid system (eCBS) and inflammatory pathways. Therefore, targeting the hepatic eCBS might have promising therapeutic potential to overcome CLDs. Experimental models of CLDs and observational studies in humans suggest that cannabis and its derivatives may exert hepatoprotective effects against CLDs through diverse pathways. However, these promising therapeutic benefits are not yet fully validated, as the few completed clinical trials on phytocannabinoids, which are thought to hold the most promising therapeutic potential (cannabidiol or tetrahydrocannabivarin), remained inconclusive. Therefore, expanding research on less studied phytocannabinoids and their derivatives, with a focus on their mode of action on liver metabolism, might provide promising advances in the development of new and original therapeutics for the management of CLDs, such as NAFLD, ALD, or even hepatitis C-induced liver disorders.<\/jats:p>","DOI":"10.3390\/ijms23169423","type":"journal-article","created":{"date-parts":[[2022,8,21]],"date-time":"2022-08-21T22:23:13Z","timestamp":1661120593000},"page":"9423","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Cannabinoids and Chronic Liver Diseases"],"prefix":"10.3390","volume":"23","author":[{"given":"Ralph-Sydney","family":"Mboumba Bouassa","sequence":"first","affiliation":[{"name":"Department of Biological Sciences and CERMO-FC Research Centre, Universit\u00e9 du Qu\u00e9bec \u00e0 Montr\u00e9al, Montreal, QC H2X 1Y4, Canada"},{"name":"Infectious Diseases and Immunity in Global Health Program, Research Institute of McGill University Health Centre, Montreal, QC H3A 3J1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2655-8283","authenticated-orcid":false,"given":"Giada","family":"Sebastiani","sequence":"additional","affiliation":[{"name":"Infectious Diseases and Immunity in Global Health Program, Research Institute of McGill University Health Centre, Montreal, QC H3A 3J1, Canada"},{"name":"Department of Medicine, Division of Gastroenterology and Hepatology, McGill University Health Centre, Montreal, QC H3A 3J1, Canada"},{"name":"Department of Medicine, Division of Infectious Diseases and Chronic Viral Illness Service, Montreal, QC H3A 3J1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Di Marzo","sequence":"additional","affiliation":[{"name":"Centre de Recherche de l\u2019Institut Universitaire de Cardiologie et de Pneumologie de Qu\u00e9bec, D\u00e9partement of M\u00e9decine, Facult\u00e9 de M\u00e9decine, Universit\u00e9 Laval, Quebec City, QC G1V 0A6, Canada"},{"name":"Canada Excellence Research Chair on the Microbiome-Endocannabinoidome Axis in Metabolic Health (CERC-MEND), Universit\u00e9 Laval, Quebec City, QC G1V 0A6, Canada"},{"name":"Endocannabinoid Research Group, Institute of Biomolecular Chemistry, Consiglio Nazionale Delle Ricerche (CNR), 80078 Pozzuoli, Italy"},{"name":"Institut sur la Nutrition et les Aliments Fonctionnels, Centre NUTRISS, \u00c9cole de Nutrition, Facult\u00e9 des Sciences de L\u2019agriculture et de L\u2019alimentation, Universit\u00e9 Laval, Quebec City, QC G1V 0A6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4321-9777","authenticated-orcid":false,"given":"Mohammad-Ali","family":"Jenabian","sequence":"additional","affiliation":[{"name":"Department of Biological Sciences and CERMO-FC Research Centre, Universit\u00e9 du Qu\u00e9bec \u00e0 Montr\u00e9al, Montreal, QC H2X 1Y4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4547-714X","authenticated-orcid":false,"given":"Cecilia T.","family":"Costiniuk","sequence":"additional","affiliation":[{"name":"Infectious Diseases and Immunity in Global Health Program, Research Institute of McGill University Health Centre, Montreal, QC H3A 3J1, Canada"},{"name":"Department of Medicine, Division of Infectious Diseases and Chronic Viral Illness Service, Montreal, QC H3A 3J1, Canada"},{"name":"Department of Microbiology and Immunology, McGill University, Montreal, QC H3A 3J1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,8,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jhep.2018.09.014","article-title":"Burden of liver diseases in the world","volume":"70","author":"Asrani","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.arcmed.2020.11.010","article-title":"Epidemiology, Pathogenesis, Diagnosis and Emerging Treatment of Nonalcoholic Fatty Liver Disease","volume":"52","author":"Makri","year":"2021","journal-title":"Arch. Med. Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"12","DOI":"10.35946\/arcr.v41.1.12","article-title":"Hepatic Cannabinoid Signaling in the Regulation of Alcohol-Associated Liver Disease","volume":"41","author":"Yang","year":"2021","journal-title":"Alcohol Res."},{"key":"ref_5","unstructured":"WHO (2022, April 24). Hepatitis. WHO (World Health Organization). Available online: https:\/\/www.who.int\/health-topics\/hepatitis#tab=tab_1."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"587628","DOI":"10.3389\/fcimb.2020.587628","article-title":"Pathogenesis of Viral Hepatitis-Induced Chronic Liver Disease: Role of Extracellular Vesicles","volume":"10","author":"Lim","year":"2020","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref_7","unstructured":"Chopra, S.L.M. (2022, July 15). Management of Nonalcoholic Fatty Liver Disease in Adults. Up To Date, Available online: https:\/\/www.uptodate.com\/contents\/management-of-nonalcoholic-fatty-liver-disease-in-adults."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Berk, K., Bzdega, W., Konstantynowicz-Nowicka, K., Charytoniuk, T., Zywno, H., and Chabowski, A. (2021). Phytocannabinoids-A Green Approach toward Non-Alcoholic Fatty Liver Disease Treatment. J. Clin. Med., 10.","DOI":"10.3390\/jcm10030393"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.tips.2015.02.008","article-title":"Endocannabinoid signaling at the periphery: 50 years after THC","volume":"36","author":"Maccarrone","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.plipres.2016.02.002","article-title":"Endocannabinoids and endocannabinoid-related mediators: Targets, metabolism and role in neurological disorders","volume":"62","author":"Iannotti","year":"2016","journal-title":"Prog. Lipid Res."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Iannotti, F.A., and Vitale, R.M. (2021). The Endocannabinoid System and PPARs: Focus on Their Signalling Crosstalk, Action and Transcriptional Regulation. Cells, 10.","DOI":"10.3390\/cells10030586"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/nrd.2018.115","article-title":"New approaches and challenges to targeting the endocannabinoid system","volume":"17","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.2174\/092986710790980078","article-title":"Endocannabinoids as regulators of transient receptor potential (TRP) channels: A further opportunity to develop new endocannabinoid-based therapeutic drugs","volume":"17","year":"2010","journal-title":"Curr. Med. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.2174\/092986710790980014","article-title":"From surface to nuclear receptors: The endocannabinoid family extends its assets","volume":"17","author":"Pistis","year":"2010","journal-title":"Curr. Med. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1002\/jcp.24959","article-title":"Anandamide drives cell cycle progression through CB1 receptors in a rat model of synchronized liver regeneration","volume":"230","author":"Pisanti","year":"2015","journal-title":"J. Cell Physiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"G357","DOI":"10.1152\/ajpgi.00456.2007","article-title":"Endocannabinoids and liver disease. II. Endocannabinoids in the pathogenesis and treatment of liver fibrosis","volume":"294","author":"Siegmund","year":"2008","journal-title":"Am. J. Physiol. Gastrointest Liver Physiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/cld.527","article-title":"Cannabinoids in liver diseases","volume":"7","author":"Patsenker","year":"2016","journal-title":"Clin. Liver Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.cmet.2013.03.001","article-title":"The endocannabinoid system in energy homeostasis and the etiopathology of metabolic disorders","volume":"17","author":"Silvestri","year":"2013","journal-title":"Cell Metab."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.4049\/jimmunol.1403205","article-title":"Endocannabinoid System Contributes to Liver Injury and Inflammation by Activation of Bone Marrow-Derived Monocytes\/Macrophages in a CB1-Dependent Manner","volume":"195","author":"Mai","year":"2015","journal-title":"J. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"12064","DOI":"10.1038\/s41598-017-10924-8","article-title":"Cannabidiol attenuates alcohol-induced liver steatosis, metabolic dysregulation, inflammation and neutrophil-mediated injury","volume":"7","author":"Wang","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1053\/j.gastro.2004.12.050","article-title":"Antifibrogenic role of the cannabinoid receptor CB2 in the liver","volume":"128","author":"Julien","year":"2005","journal-title":"Gastroenterology"},{"key":"ref_23","first-page":"58","article-title":"Endocannabinoids as novel mediators of liver diseases","volume":"29","author":"Mallat","year":"2006","journal-title":"J. Endocrinol. Investig."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/acer.14306","article-title":"Interactions Between Alcohol and the Endocannabinoid System","volume":"44","author":"Kunos","year":"2020","journal-title":"Alcohol Clin. Exp. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1152\/physrev.00002.2016","article-title":"From Phytocannabinoids to Cannabinoid Receptors and Endocannabinoids: Pleiotropic Physiological and Pathological Roles Through Complex Pharmacology","volume":"96","author":"Ligresti","year":"2016","journal-title":"Physiol. Rev."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Kopustinskiene, D.M., Masteikova, R., Lazauskas, R., and Bernatoniene, J. (2022). Cannabis sativa L. Bioactive Compounds and Their Protective Role in Oxidative Stress and Inflammation. Antioxidants, 11.","DOI":"10.3390\/antiox11040660"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"108448","DOI":"10.1016\/j.intimp.2021.108448","article-title":"Immunosuppressive activity of non-psychoactive Cannabis sativa L. extract on the function of human T lymphocytes","volume":"103","author":"Devi","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.bcp.2008.06.022","article-title":"The profile of immune modulation by cannabidiol (CBD) involves deregulation of nuclear factor of activated T cells (NFAT)","volume":"76","author":"Kaplan","year":"2008","journal-title":"Biochem. Pharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.freeradbiomed.2011.02.021","article-title":"Cannabidiol protects against hepatic ischemia\/reperfusion injury by attenuating inflammatory signaling and response, oxidative\/nitrative stress, and cell death","volume":"50","author":"Mukhopadhyay","year":"2011","journal-title":"Free Radic. Biol. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e170","DOI":"10.1038\/cddis.2011.52","article-title":"Cannabidiol causes activated hepatic stellate cell death through a mechanism of endoplasmic reticulum stress-induced apoptosis","volume":"2","author":"Lim","year":"2011","journal-title":"Cell Death Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.freeradbiomed.2013.12.026","article-title":"Cannabidiol protects liver from binge alcohol-induced steatosis by mechanisms including inhibition of oxidative stress and increase in autophagy","volume":"68","author":"Yang","year":"2014","journal-title":"Free Radic. Biol. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1016\/j.jhep.2015.01.001","article-title":"Two non-psychoactive cannabinoids reduce intracellular lipid levels and inhibit hepatosteatosis","volume":"62","author":"Silvestri","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"21224","DOI":"10.1002\/jcp.28728","article-title":"Cannabidiol protects livers against nonalcoholic steatohepatitis induced by high-fat high cholesterol diet via regulating NF-\u03baB and NLRP3 inflammasome pathway","volume":"234","author":"Huang","year":"2019","journal-title":"J. Cell Physiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"724747","DOI":"10.3389\/fphar.2021.724747","article-title":"CBD Alleviates Liver Injuries in Alcoholics With High-Fat High-Cholesterol Diet Through Regulating NLRP3 Inflammasome-Pyroptosis Pathway","volume":"12","author":"Jiang","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.2337\/dc16-0650","article-title":"Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study","volume":"39","author":"Jadoon","year":"2016","journal-title":"Diabetes Care"},{"key":"ref_36","unstructured":"Clinicaltrials.gov (2022, May 23). Study to Assess the Effect of Cannabidiol on Liver Fat Levels in Subjects with Fatty Liver Disease, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT01284634."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1111\/j.1476-5381.2008.00107.x","article-title":"Synthetic and plant-derived cannabinoid receptor antagonists show hypophagic properties in fasted and non-fasted mice","volume":"156","author":"Riedel","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1111\/j.1476-5381.2011.01410.x","article-title":"\u03948-Tetrahydrocannabivarin prevents hepatic ischaemia\/reperfusion injury by decreasing oxidative stress and inflammatory responses through cannabinoid CB2 receptors","volume":"165","author":"Mukhopadhyay","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.1038\/nutd.2013.9","article-title":"The cannabinoid \u0394(9)-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity","volume":"3","author":"Wargent","year":"2013","journal-title":"Nutr. Diabetes"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"113693","DOI":"10.1016\/j.bcp.2019.113693","article-title":"Tetrahydrocannabinolic acid A (THCA-A) reduces adiposity and prevents metabolic disease caused by diet-induced obesity","volume":"171","author":"Palomares","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"153426","DOI":"10.1016\/j.phymed.2020.153426","article-title":"\u03949-Tetrahydrocannabinolic Acid markedly alleviates liver fibrosis and inflammation in mice","volume":"81","author":"Prados","year":"2021","journal-title":"Phytomedicine"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3389\/fendo.2020.00103","article-title":"The Atypical Cannabinoid Abn-CBD Reduces Inflammation and Protects Liver, Pancreas, and Adipose Tissue in a Mouse Model of Prediabetes and Non-alcoholic Fatty Liver Disease","volume":"11","author":"Lara","year":"2020","journal-title":"Front. Endocrinol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/hep.24524","article-title":"Cannabinoid CB2 receptors protect against alcoholic liver disease by regulating Kupffer cell polarization in mice","volume":"54","author":"Louvet","year":"2011","journal-title":"Hepatology"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Melgar-Lesmes, P., Perramon, M., and Jim\u00e9nez, W. (2019). Roles of the Hepatic Endocannabinoid and Apelin Systems in the Pathogenesis of Liver Fibrosis. Cells, 8.","DOI":"10.3390\/cells8111311"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.bbrc.2013.06.033","article-title":"Fatty acid amide hydrolase but not monoacyl glycerol lipase controls cell death induced by the endocannabinoid 2-arachidonoyl glycerol in hepatic cell populations","volume":"437","author":"Siegmund","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"6323","DOI":"10.1073\/pnas.1017689108","article-title":"Hyperactivation of anandamide synthesis and regulation of cell-cycle progression via cannabinoid type 1 (CB1) receptors in the regenerating liver","volume":"108","author":"Mukhopadhyay","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1242\/dev.121731","article-title":"Cannabinoid receptor signaling regulates liver development and metabolism","volume":"143","author":"Liu","year":"2016","journal-title":"Development"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.2337\/db12-0901","article-title":"Developmental role for endocannabinoid signaling in regulating glucose metabolism and growth","volume":"62","author":"Li","year":"2013","journal-title":"Diabetes"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1111\/j.1478-3231.2010.02298.x","article-title":"Cannabinoid receptor 1 and 2 agonists increase lipid accumulation in hepatocytes","volume":"30","author":"Spahr","year":"2010","journal-title":"Liver. Int."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Bazwinsky-Wutschke, I., Zipprich, A., and Dehghani, F. (2019). Endocannabinoid System in Hepatic Glucose Metabolism, Fatty Liver Disease, and Cirrhosis. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20102516"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"38041","DOI":"10.1074\/jbc.M112.377978","article-title":"Activation of cannabinoid receptor type 1 (Cb1r) disrupts hepatic insulin receptor signaling via cyclic AMP-response element-binding protein H (Crebh)-mediated induction of Lipin1 gene","volume":"287","author":"Chanda","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"780496","DOI":"10.3389\/fphar.2022.780496","article-title":"The NLRP3 Inflammasome in Non-Alcoholic Fatty Liver Disease and Steatohepatitis: Therapeutic Targets and Treatment","volume":"13","author":"Yu","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/S1262-3636(08)74604-4","article-title":"Cannabinoid receptors as novel therapeutic targets for the management of non-alcoholic steatohepatitis","volume":"34","author":"Mallat","year":"2008","journal-title":"Diabetes Metab."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"6109","DOI":"10.3748\/wjg.14.6109","article-title":"Role of cannabinoids in chronic liver diseases","volume":"14","author":"Parfieniuk","year":"2008","journal-title":"World J. Gastroenterol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1007\/BF03348205","article-title":"Antagonizing the cannabinoid receptor type 1: A dual way to fight obesity","volume":"26","author":"Cota","year":"2003","journal-title":"J. Endocrinol. Investig."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"18832","DOI":"10.1073\/pnas.1309469110","article-title":"Monounsaturated fatty acids generated via stearoyl CoA desaturase-1 are endogenous inhibitors of fatty acid amide hydrolase","volume":"110","author":"Liu","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1172\/JCI200523057","article-title":"Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity","volume":"115","author":"DePetrillo","year":"2005","journal-title":"J. Clin. Investig."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1172\/JCI34827","article-title":"Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice","volume":"118","author":"Liu","year":"2008","journal-title":"J. Clin. Investig."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Dibba, P., Li, A., Cholankeril, G., Iqbal, U., Gadiparthi, C., Khan, M.A., Kim, D., and Ahmed, A. (2018). Mechanistic Potential and Therapeutic Implications of Cannabinoids in Nonalcoholic Fatty Liver Disease. Medicines, 5.","DOI":"10.3390\/medicines5020047"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1021\/acsptsci.0c00213","article-title":"Peripherally Selective CB1 Receptor Antagonist Improves Symptoms of Metabolic Syndrome in Mice","volume":"4","author":"Khan","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1172\/JCI42551","article-title":"Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity","volume":"120","author":"Tam","year":"2010","journal-title":"J. Clin. Investig."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.omtn.2020.04.010","article-title":"Cannabinoid Receptor 1\/miR-30b-5p Axis Governs Macrophage NLRP3 Expression and Inflammasome Activation in Liver Inflammatory Disease","volume":"20","author":"Yang","year":"2020","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e152242","DOI":"10.1172\/JCI152242","article-title":"Cannabinoid receptor 1 signaling in hepatocytes and stellate cells does not contribute to NAFLD","volume":"131","author":"Wang","year":"2021","journal-title":"J. Clin. Investig."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e155330","DOI":"10.1172\/JCI155330","article-title":"Do endocannabinoids acting via hepatic CB-1 contribute to NAFLD and hepatic insulin resistance?","volume":"132","author":"Kunos","year":"2022","journal-title":"J. Clin. Investig."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Deveaux, V., Cadoudal, T., Ichigotani, Y., Teixeira-Clerc, F., Louvet, A., Manin, S., Nhieu, J.T., Belot, M.P., Zimmer, A., and Even, P. (2009). Cannabinoid CB2 receptor potentiates obesity-associated inflammation, insulin resistance and hepatic steatosis. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0005844"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1007\/s00125-010-1894-6","article-title":"Deficiency of CB2 cannabinoid receptor in mice improves insulin sensitivity but increases food intake and obesity with age","volume":"53","author":"Agudo","year":"2010","journal-title":"Diabetologia"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1111\/liv.12263","article-title":"The endocannabinoid system in advanced liver cirrhosis: Pathophysiological implication and future perspectives","volume":"33","author":"Baldassarre","year":"2013","journal-title":"Liver Int."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1002\/mnfr.201600197","article-title":"\u03b2-Caryophyllene attenuates palmitate-induced lipid accumulation through AMPK signaling by activating CB2 receptor in human HepG2 hepatocytes","volume":"60","author":"Kamikubo","year":"2016","journal-title":"Mol. Nutr. Food Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/bph.13722","article-title":"\u03b2-Caryophyllene protects against alcoholic steatohepatitis by attenuating inflammation and metabolic dysregulation in mice","volume":"175","author":"Varga","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.2741\/4468","article-title":"Endocannabinoids signaling: Molecular mechanisms of liver regulation and diseases","volume":"21","author":"Wang","year":"2016","journal-title":"Front. Biosci."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/1440-1681.12967","article-title":"The endocannabinoid-alcohol crosstalk: Recent advances on a bi-faceted target","volume":"45","author":"Lavanco","year":"2018","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.2119\/molmed.2011.00149","article-title":"Cannabinoid receptor type I modulates alcohol-induced liver fibrosis","volume":"17","author":"Patsenker","year":"2011","journal-title":"Mol. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.cmet.2007.12.007","article-title":"Paracrine activation of hepatic CB1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver","volume":"7","author":"Jeong","year":"2008","journal-title":"Cell Metab."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"4370","DOI":"10.1021\/acs.jmedchem.7b01820","article-title":"Blocking Alcoholic Steatosis in Mice with a Peripherally Restricted Purine Antagonist of the Type 1 Cannabinoid Receptor","volume":"61","author":"Amato","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"28806","DOI":"10.1038\/srep28806","article-title":"The Cannabinoid Receptor 2 Protects Against Alcoholic Liver Disease Via a Macrophage Autophagy-Dependent Pathway","volume":"6","author":"Lodder","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1111\/j.1478-3231.2011.02496.x","article-title":"Role of cannabinoid receptors in alcoholic hepatic injury: Steatosis and fibrogenesis are increased in CB2 receptor-deficient mice and decreased in CB1 receptor knockouts","volume":"31","author":"Trebicka","year":"2011","journal-title":"Liver Int."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ijid.2013.12.017","article-title":"Endocannabinoid system activation contributes to glucose metabolism disorders of hepatocytes and promotes hepatitis C virus replication","volume":"23","author":"Sun","year":"2014","journal-title":"Int. J. Infect. Dis."},{"key":"ref_78","first-page":"619","article-title":"Association between lipid accumulation and the cannabinoid system in Huh7 cells expressing HCV genes","volume":"27","author":"Toyoda","year":"2011","journal-title":"Int. J. Mol. Med."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"van der Poorten, D., Shahidi, M., Tay, E., Sesha, J., Tran, K., McLeod, D., Milliken, J.S., Ho, V., Hebbard, L.W., and Douglas, M.W. (2010). Hepatitis C virus induces the cannabinoid receptor 1. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0012841"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"7057","DOI":"10.3390\/ijms16047057","article-title":"Elevated levels of endocannabinoids in chronic hepatitis C may modulate cellular immune response and hepatic stellate cell activation","volume":"16","author":"Patsenker","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.cgh.2013.05.008","article-title":"Association between a polymorphism in cannabinoid receptor 2 and severe necroinflammation in patients with chronic hepatitis C","volume":"12","author":"Coppola","year":"2014","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Sagnelli, C., Uberti-Foppa, C., Hasson, H., Bellini, G., Minichini, C., Salpietro, S., Messina, E., Barbanotti, D., Merli, M., and Punzo, F. (2017). Cannabinoid receptor 2-63 RR variant is independently associated with severe necroinflammation in HIV\/HCV coinfected patients. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0181890"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Adejumo, A.C., Alliu, S., Ajayi, T.O., Adejumo, K.L., Adegbala, O.M., Onyeakusi, N.E., Akinjero, A.M., Durojaiye, M., and Bukong, T.N. (2017). Cannabis use is associated with reduced prevalence of non-alcoholic fatty liver disease: A cross-sectional study. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0176416"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.amjmed.2013.03.002","article-title":"The impact of marijuana use on glucose, insulin, and insulin resistance among US adults","volume":"126","author":"Penner","year":"2013","journal-title":"Am. J. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1093\/aje\/kwr200","article-title":"Obesity and cannabis use: Results from 2 representative national surveys","volume":"174","year":"2011","journal-title":"Am. J. Epidemiol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1093\/ije\/dyz044","article-title":"Are cannabis users less likely to gain weight? Results from a national 3-year prospective study","volume":"48","author":"Alshaarawy","year":"2019","journal-title":"Int. J. Epidemiol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.amjmed.2015.10.019","article-title":"Metabolic Syndrome Among Marijuana Users in the United States: An Analysis of National Health and Nutrition Examination Survey Data","volume":"129","author":"Vidot","year":"2016","journal-title":"Am. J. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"e000494","DOI":"10.1136\/bmjopen-2011-000494","article-title":"Decreased prevalence of diabetes in marijuana users: Cross-sectional data from the National Health and Nutrition Examination Survey (NHANES) III","volume":"2","author":"Rajavashisth","year":"2012","journal-title":"BMJ Open"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Kim, D., Kim, W., Kwak, M.S., Chung, G.E., Yim, J.Y., and Ahmed, A. (2017). Inverse association of marijuana use with nonalcoholic fatty liver disease among adults in the United States. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0186702"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1111\/liv.13696","article-title":"Cannabis use is associated with reduced prevalence of progressive stages of alcoholic liver disease","volume":"38","author":"Adejumo","year":"2018","journal-title":"Liver Int."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"324","DOI":"10.2174\/1570162X19666210519151320","article-title":"Lack of Association Between Recent Cannabis Use and Advanced Liver Fibrosis Among HIV-positive Heavy Drinkers","volume":"19","author":"Fuster","year":"2021","journal-title":"Curr. HIV Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1080\/14787210.2021.1884545","article-title":"Cannabis use and reduced risk of elevated fatty liver index in HIV-HCV co-infected patients: A longitudinal analysis (ANRS CO13 HEPAVIH)","volume":"19","author":"Lacombe","year":"2021","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Barr\u00e9, T., Pol, S., Ramier, C., Di Beo, V., Carrat, F., Bureau, M., Bourli\u00e8re, M., Dorival, C., Serfaty, L., and Asselah, T. (2021). Cannabis Use Is Inversely Associated with Overweight and Obesity in Hepatitis B Virus-Infected Patients (ANRS CO22 Hepather Cohort). Cannabis Cannabinoid Res.","DOI":"10.3390\/jcm11206135"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1111\/jvh.13380","article-title":"Cannabis use is associated with a lower risk of diabetes in chronic hepatitis C-infected patients (ANRS CO22 Hepather cohort)","volume":"27","author":"Nishimwe","year":"2020","journal-title":"J. Viral Hepat."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/jvh.12797","article-title":"Daily cannabis and reduced risk of steatosis in human immunodeficiency virus and hepatitis C virus-co-infected patients (ANRS CO13-HEPAVIH)","volume":"25","author":"Nordmann","year":"2018","journal-title":"J. Viral Hepat."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1093\/cid\/ciw350","article-title":"Marijuana Use Is Not Associated With Progression to Advanced Liver Fibrosis in HIV\/Hepatitis C Virus-coinfected Women","volume":"63","author":"Kelly","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1093\/cid\/civ217","article-title":"Cannabis Use and Reduced Risk of Insulin Resistance in HIV-HCV Infected Patients: A Longitudinal Analysis (ANRS CO13 HEPAVIH)","volume":"61","author":"Carrieri","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/hep.20733","article-title":"Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C","volume":"42","author":"Nguyen","year":"2005","journal-title":"Hepatology"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1053\/j.gastro.2007.11.039","article-title":"Daily cannabis use: A novel risk factor of steatosis severity in patients with chronic hepatitis C","volume":"134","author":"Zafrani","year":"2008","journal-title":"Gastroenterology"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1177\/0269881118822173","article-title":"Effect of cannabis on weight and metabolism in first-episode non-affective psychosis: Results from a three-year longitudinal study","volume":"33","author":"Castro","year":"2019","journal-title":"J. Psychopharmacol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"949","DOI":"10.3389\/fgene.2020.00949","article-title":"Does Cannabis Intake Protect Against Non-alcoholic Fatty Liver Disease? A Two-Sample Mendelian Randomization Study","volume":"11","author":"Wang","year":"2020","journal-title":"Front. Genet."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"106","DOI":"10.14309\/ajg.0000000000000833","article-title":"Obesity, Diabetes, Coffee, Tea, and Cannabis Use Alter Risk for Alcohol-Related Cirrhosis in 2 Large Cohorts of High-Risk Drinkers","volume":"116","author":"Whitfield","year":"2021","journal-title":"Am. J. Gastroenterol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cgh.2007.10.021","article-title":"Influence of cannabis use on severity of hepatitis C disease","volume":"6","author":"Ishida","year":"2008","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1093\/cid\/cit378","article-title":"Marijuana smoking does not accelerate progression of liver disease in HIV-hepatitis C coinfection: A longitudinal cohort analysis","volume":"57","author":"Brunet","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1155\/2014\/804969","article-title":"Marijuana use in hepatitis C infection does not affect liver biopsy histology or treatment outcomes","volume":"28","author":"Liu","year":"2014","journal-title":"Can. J. Gastroenterol. Hepatol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1155\/2008\/725702","article-title":"Evaluation of oral cannabinoid-containing medications for the management of interferon and ribavirin-induced anorexia, nausea and weight loss in patients treated for chronic hepatitis C virus","volume":"22","author":"Costiniuk","year":"2008","journal-title":"Can. J. Gastroenterol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1097\/01.meg.0000216934.22114.51","article-title":"Cannabis use improves retention and virological outcomes in patients treated for hepatitis C","volume":"18","author":"Sylvestre","year":"2006","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1097\/QAD.0000000000002481","article-title":"Reply to: Benefits of cannabis use for metabolic disorders and survival in people living with HIV with or without hepatitis C","volume":"34","author":"Costiniuk","year":"2020","journal-title":"Aids"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/jcag\/gwy064","article-title":"Canadian Association of Gastroenterology Position Statement: Use of Cannabis in Gastroenterological and Hepatic Disorders","volume":"2","author":"Andrews","year":"2019","journal-title":"J. Can. Assoc. Gastroenterol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/2045125312457586","article-title":"Cannabis, a complex plant: Different compounds and different effects on individuals","volume":"2","author":"Atakan","year":"2020","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"627","DOI":"10.3389\/fphar.2019.00627","article-title":"Therapeutic Prospects of Cannabidiol for Alcohol Use Disorder and Alcohol-Related Damages on the Liver and the Brain","volume":"10","author":"Naassila","year":"2019","journal-title":"Front. Pharmacol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1080\/1028415X.2001.11747361","article-title":"Delta9-tetrahydrocannabinol stimulates palatable food intake in Lewis rats: Effects of peripheral and central administration","volume":"4","author":"Koch","year":"2001","journal-title":"Nutr. Neurosci."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/sj.bjp.0706157","article-title":"CB1 cannabinoid receptor-mediated modulation of food intake in mice","volume":"145","author":"Wiley","year":"2005","journal-title":"Br. J. Pharmacol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1194\/jlr.M082644","article-title":"\u0394(9)-Tetrahydrocannabinol induces endocannabinoid accumulation in mouse hepatocytes: Antagonism by Fabp1 gene ablation","volume":"59","author":"McIntosh","year":"2018","journal-title":"J. Lipid Res."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/j.1478-3231.2009.02137.x","article-title":"Circulating and hepatic endocannabinoids and endocannabinoid-related molecules in patients with cirrhosis","volume":"30","author":"Caraceni","year":"2010","journal-title":"Liver Int."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"4790","DOI":"10.1111\/bph.13250","article-title":"Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor","volume":"172","author":"Laprairie","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/sj.bjp.0707442","article-title":"The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin","volume":"153","author":"Pertwee","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Rakotoarivelo, V., Sihag, J., and Flamand, N. (2021). Role of the Endocannabinoid System in the Adipose Tissue with Focus on Energy Metabolism. Cells, 10.","DOI":"10.3390\/cells10061279"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/s41401-018-0031-9","article-title":"GPR3, GPR6, and GPR12 as novel molecular targets: Their biological functions and interaction with cannabidiol","volume":"40","author":"Laun","year":"2019","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"116","DOI":"10.4103\/0974-8490.199780","article-title":"Potential of Cannabidiol for the Treatment of Viral Hepatitis","volume":"9","author":"Lowe","year":"2017","journal-title":"Pharmacogn. Res."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"777804","DOI":"10.3389\/fphar.2021.777804","article-title":"Minor Cannabinoids: Biosynthesis, Molecular Pharmacology and Potential Therapeutic Uses","volume":"12","author":"Walsh","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1111\/bcp.14038","article-title":"A systematic review of cannabidiol dosing in clinical populations","volume":"85","author":"Millar","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1476-5381.2010.01127.x","article-title":"Principles of early drug discovery","volume":"162","author":"Hughes","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s43094-020-00047-9","article-title":"Exploring different approaches to improve the success of drug discovery and development projects: A review","volume":"6","author":"Kiriiri","year":"2020","journal-title":"Future J. Pharm. Sci."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Nielsch, U., Fuhrmann, U., and Jaroch, S. (2016). New Approaches to Drug Discovery, Springer Nature.","DOI":"10.1007\/978-3-319-28914-4"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1016\/j.apsb.2022.02.002","article-title":"Why 90% of clinical drug development fails and how to improve it?","volume":"12","author":"Sun","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/14740338.2017.1397128","article-title":"Drug-drug interactions as a result of co-administering \u0394(9)-THC and CBD with other psychotropic agents","volume":"17","author":"Rong","year":"2018","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3138\/canlivj.2018-0023","article-title":"Cannabis and the liver: Things you wanted to know but were afraid to ask","volume":"2","author":"Zhu","year":"2019","journal-title":"Can. Liver J."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3109\/03602532.2013.849268","article-title":"Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: A systematic review","volume":"46","author":"Stout","year":"2014","journal-title":"Drug Metab. Rev."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"332","DOI":"10.2133\/dmpk.DMPK-12-RG-129","article-title":"Cannabidiol is a potent inhibitor of the catalytic activity of cytochrome P450 2C19","volume":"28","author":"Jiang","year":"2013","journal-title":"Drug Metab. Pharm."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/16\/9423\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:13:00Z","timestamp":1760141580000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/16\/9423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,20]]},"references-count":130,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2022,8]]}},"alternative-id":["ijms23169423"],"URL":"https:\/\/doi.org\/10.3390\/ijms23169423","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,20]]}}}